A detailed history of Brown, Lisle/Cummings, Inc. transactions in Novartis Ag stock. As of the latest transaction made, Brown, Lisle/Cummings, Inc. holds 1,973 shares of NVS stock, worth $204,817. This represents 0.07% of its overall portfolio holdings.

Number of Shares
1,973
Previous 1,908 3.41%
Holding current value
$204,817
Previous $203 Million 11.72%
% of portfolio
0.07%
Previous 0.07%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$106.13 - $120.89 $6,898 - $7,857
65 Added 3.41%
1,973 $227 Million
Q2 2024

Jul 17, 2024

BUY
$92.57 - $107.37 $94,421 - $109,517
1,020 Added 114.86%
1,908 $203 Million
Q1 2023

Jun 28, 2024

BUY
$80.03 - $92.81 $8,003 - $9,281
100 Added 12.69%
888 $81.7 Million
Q4 2022

Jun 28, 2024

BUY
$75.55 - $92.52 $10,425 - $12,767
138 Added 21.23%
788 $71.5 Million
Q4 2021

Jun 28, 2024

BUY
$79.7 - $88.13 $51,805 - $57,284
650 New
650 $56.9 Million

Others Institutions Holding NVS

About NOVARTIS AG


  • Ticker NVS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,151,000,064
  • Market Cap $223B
  • Description
  • Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...
More about NVS
Track This Portfolio

Track Brown, Lisle/Cummings, Inc. Portfolio

Follow Brown, Lisle/Cummings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brown, Lisle/Cummings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Brown, Lisle/Cummings, Inc. with notifications on news.